Cytokinetics Inc. | Mutual Funds
Mutual Funds that own Cytokinetics Inc.
iShares Core S&P Small Cap ETF
2,843,741
5.21%
804
0.05%
09/06/2018
Vanguard Total Stock Market Index Fund
1,174,595
2.15%
0
0%
07/31/2018
iShares Russell 2000 ETF
962,426
1.76%
-513
0.02%
09/06/2018
Fidelity Select Biotechnology Portfolio
842,410
1.54%
-70,654
0.07%
07/31/2018
SPDR S&P Biotech ETF
760,158
1.39%
1,956
0.1%
09/06/2018
Vanguard Extended Market Index Fund
675,618
1.24%
0
0.01%
07/31/2018
Wasatch Small Cap Growth Fund
640,249
1.17%
0
0.24%
03/31/2018
iShares Nasdaq Biotechnology ETF
623,946
1.13%
-8,169
0.05%
09/06/2018
PowerShares S&P Small Cap Health Care Portfolio
585,607
1.07%
37,235
0.37%
09/05/2018
Vanguard Explorer Fund
492,604
0.9%
-87,146
0.02%
06/30/2018
| Address |
280 East Grand Avenue
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.cytokinetics.com |
| Updated |
07/08/2019 |
| Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. |
